Tonix Pharmaceuticals Holding Corp.
TNXP
$13.22
$1.2410.35%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.56M | 13.11M | 10.30M | 9.83M | 10.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.56M | 13.11M | 10.30M | 9.83M | 10.04M |
| Cost of Revenue | 7.28M | 6.64M | 6.77M | 6.95M | 7.05M |
| Gross Profit | 10.28M | 6.47M | 3.53M | 2.88M | 2.99M |
| SG&A Expenses | 106.20M | 87.68M | 67.59M | 49.60M | 40.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 168.74M | 138.81M | 110.20M | 92.22M | 82.49M |
| Operating Income | -151.19M | -125.70M | -99.90M | -82.38M | -72.45M |
| Income Before Tax | -147.39M | -124.02M | -99.22M | -81.42M | -131.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -147.39 | -124.02 | -99.22 | -81.42 | -131.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -147.39M | -124.02M | -99.22M | -81.42M | -131.93M |
| EBIT | -151.19M | -125.70M | -99.90M | -82.38M | -72.45M |
| EBITDA | -149.20M | -123.78M | -97.96M | -79.90M | -69.54M |
| EPS Basic | -14.35 | -14.26 | -20.05 | -39.15 | -1.96K |
| Normalized Basic EPS | -8.97 | -8.69 | -12.31 | -24.25 | -323.87 |
| EPS Diluted | -14.35 | -14.26 | -20.05 | -39.15 | -1.96K |
| Normalized Diluted EPS | -8.97 | -8.69 | -12.31 | -24.25 | -323.87 |
| Average Basic Shares Outstanding | 41.76M | 33.98M | 24.44M | 16.14M | 8.86M |
| Average Diluted Shares Outstanding | 41.76M | 33.98M | 24.44M | 16.14M | 8.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |